| Ytd | -74.29% | |
| 1y | -34.40% |
| Open | 6.91 | Prev Close | 6.98 | Low | 6.86 | High | 7.08 | Mkt Cap | 379.85M |
| Vol | 334.83K | Avg Vol | 573.32K | EPS | -2.91 | P/E | -2.40 | Forward P/E | -2.45 |
| Beta | 1.23 | Short Ratio | 2.45 | Inst. Own | 94.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 7.45 | 200-d Avg | 16.47 | 1yr Est | 47.86 |
UPB News
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasa
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of m
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage
WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage
I am initiating a Buy rating on Verekitug, the lead asset of Upstream Bio, a small-cap biotech tradi
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensu
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with conveni
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-sta
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, a
The company reported a cash position of $341.5 million, expected to fund planned operations through
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a h
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be pre
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage
Upstream Bio Inc. (NASDAQ: UPB) shares are trading lower during Friday's session as the stock reacts
The stock gave up its gains and is falling, probably on profit booking.